New published data
HUB Organoids™ advance treatment for Cystic Fibrosis
Promoting full-length CFTR protein production is a requisite step to address some of the remaining unmet medical need for Cystic Fibrosis (CF) patients carrying the nonsense allele G542X
Read this paper to discover:
- How ELX-02 treatment (Eloxx Pharmaceuticals, Inc.) can restore CFTR protein expression in patient-derived organoids
- How data obtained using HUB Organoids™ further supports the on-going clinical evaluation of ELX-02 as a read-through agent for CF caused by the G542X allele.